These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29573648)

  • 21. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial.
    Shaywitz S; Shaywitz B; Wietecha L; Wigal S; McBurnett K; Williams D; Kronenberger WG; Hooper SR
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):19-28. PubMed ID: 27410907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
    Wietecha LA; Clemow DB; Buchanan AS; Young JL; Sarkis EH; Findling RL
    CNS Neurosci Ther; 2016 Jul; 22(7):546-57. PubMed ID: 26922462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial.
    McElroy SL; Guerdjikova A; Kotwal R; Welge JA; Nelson EB; Lake KA; Keck PE; Hudson JI
    J Clin Psychiatry; 2007 Mar; 68(3):390-8. PubMed ID: 17388708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study.
    Scott TM; Rivera Mindt M; Cunningham CO; Arias F; Coulehan K; Mangalonzo A; Olsen P; Arnsten JH
    Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):48. PubMed ID: 29141650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
    Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
    Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.
    Kowalczyk WJ; Phillips KA; Jobes ML; Kennedy AP; Ghitza UE; Agage DA; Schmittner JP; Epstein DH; Preston KL
    Am J Psychiatry; 2015 Aug; 172(8):760-7. PubMed ID: 25783757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults.
    Marsch LA; Moore SK; Borodovsky JT; Solhkhah R; Badger GJ; Semino S; Jarrett K; Condon KD; Rossettie K; Vincent P; Hajizadeh N; Ducat E
    Addiction; 2016 Aug; 111(8):1406-15. PubMed ID: 26918564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrarapid Influence of Buprenorphine on Major Depression in Opioid-Dependent Patients: A Double Blind, Randomized Clinical Trial.
    Ahmadi J; Sefidfard Jahromi M
    Subst Use Misuse; 2018 Jan; 53(2):286-289. PubMed ID: 29148881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
    Jain K; Jain R; Dhawan A
    J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interim buprenorphine treatment in opiate dependence: A pilot effectiveness study.
    Abrahamsson T; Widinghoff C; Lilliebladh A; Gedeon C; Nilvall K; Hakansson A
    Subst Abus; 2016; 37(1):104-9. PubMed ID: 26176490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of behavioral treatment conditions in buprenorphine maintenance.
    Ling W; Hillhouse M; Ang A; Jenkins J; Fahey J
    Addiction; 2013 Oct; 108(10):1788-98. PubMed ID: 23734858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
    Ahmadi J; Sahraian A; Biuseh M
    Trials; 2019 Jul; 20(1):468. PubMed ID: 31362784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
    D'Onofrio G; O'Connor PG; Pantalon MV; Chawarski MC; Busch SH; Owens PH; Bernstein SL; Fiellin DA
    JAMA; 2015 Apr; 313(16):1636-44. PubMed ID: 25919527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone.
    Oliveto AH; Feingold A; Schottenfeld R; Jatlow P; Kosten TR
    Arch Gen Psychiatry; 1999 Sep; 56(9):812-20. PubMed ID: 12884887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.